{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "MVA-BN_Smallpox_Vaccine",
  "nciThesaurus": {
    "casRegistry": "1026718-04-6",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, with potential antineoplastic activity. Upon intratumoral administration, MVA-BN smallpox vaccine may induce both cellular and humoral immune responses, which may lead to tumor cell lysis.",
    "fdaUniiCode": "TU8J357395",
    "identifier": "C173552",
    "preferredName": "MVA-BN Smallpox Vaccine",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1663",
      "C1920"
    ],
    "synonyms": [
      "Imvamune",
      "Imvanex",
      "JYNNEOS",
      "MVA Smallpox Vaccine",
      "MVA-BN Smallpox Vaccine",
      "Modified Vaccinia Ankara - Bavarian Nordic Smallpox Vaccine",
      "Modified Vaccinia Ankara Smallpox Vaccine",
      "VACCINIA VIRUS MODIFIED STRAIN ANKARA-BAVARIAN NORDIC NON-REPLICATING ANTIGEN"
    ]
  }
}